ApoA1 mimetics (e.g., L-4F and D-4F), recombinant apoA1 protein CER-001, a formulation of apoA1 CSL-112 obtained from plasma, and autologous administration of apoA1 obtained from the patient all showed good tolerability results in the first phase of clinical trials for ACS or stable coronary heart disease [29]. This evidence concerns the gene APOA1 and coronary artery disorder.